Committees’ consolidated opinions available on applications for authorisation
The consolidated opinions of the Committees for Risk Assessment (RAC) and Socio-economic Analysis (SEAC) are available for applications of authorisation for 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated by Octapharma AB, Octapharma Pharmazeutika Produktionsgesellschaft m.b.H, Octapharma S.A.S. and Octapharma Produktionsgesellschaft Deutschland mbH.